Hospital Delivery Charges Significantly Higher When Babies Conceived Through Assisted Reproductive Technologies
By Miriam Zoll,
Reporting on Health
| 03. 04. 2014
A new study published in the Journal of Perinatology [1] online has found that from 2009-2011 in California, hospital delivery charges associated with babies born through assisted reproductive technologies (ART) or artificial insemination (AI) were significantly higher than charges for babies born through natural conception –– in some cases exceeding $1.2 million per infant.
The retrospective study was based on 2009-2011 data from the California Office of Statewide Health Planning and Development and conducted by researchers from the Loma Linda University School of Medicine.
In 2011, statewide average hospital charges for maternity care for women who delivered ART/AI infants were almost fifty percent higher than fees for non-ART infants born late preterm or at term––$35,768 compared to $18,654. The higher charges are linked to a 24- to 27-fold increase across California of multiple births, and significantly higher rates of preterm births, lower birth weights, fetal anomalies and stillbirth, among infants born through ART/AI. In 2009, there were 5,710 ART/AI live births in California and 1,718 of these births -- or 30.1 percent –– were multiple births consisting of twins, triplets...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...